Dr. Emi H. Caywood
Claim this profileAlfred I duPont Hospital for Children
Studies Acute Lymphoblastic Leukemia
Studies Acute Leukemia
23 reported clinical trials
63 drugs studied
About Emi H. Caywood
Education:
- Earned an MD from the University of Medicine and Dentistry of New Jersey in 2002.
- Completed a Residency in Pediatrics at Georgetown University Hospital in 2005.
- Finished a Fellowship in Pediatric Hematology/Oncology at Johns Hopkins University in 2009.
Experience:
- Board Certified in Pediatrics and Pediatric Hematology-Oncology.
- Recognized as a Top Doctor by Delaware Today magazine in 2014 and a Hyundai Hope on Wheels Grant Scholar in 2008.
- Specializes in treating children with cancers and blood disorders at Nemours Children's Health, Philadelphia, PA.
Area of expertise
1Acute Lymphoblastic Leukemia
Stage IV
BCR-ABL1 fusion positive
ABL-class fusion positive
2Acute Leukemia
BCR-ABL1 positive
BCR-ABL1 T315I positive
Philadelphia chromosome positive
Affiliated Hospitals
Clinical Trials Emi H. Caywood is currently running
Non-TBI Conditioning
for HCT in Acute Lymphoblastic Leukemia
This study will evaluate the use of non- TBI (total body irradiation) conditioning for B-ALL patients with low risk of relapse as defined by absence of NGS-MRD (next generation sequencing minimal residual disease) before receiving a hematopoietic cell transplant (HCT). Patients diagnosed with B-ALL who are candidates for HCT will be screened by NGS-MRD on a test of bone marrow done before the HCT. Subjects who are pre-HCT NGS-MRD negative will be eligible to receive a non-TBI conditioning regimen as part of the treatment cohort of the study. Subjects who are pre-HCT NGS-MRD positive will be treated as per treating center standard and will be followed in an observational cohort (HCT center standard of care).
Recruiting1 award Phase 2
CPX-351 + Gilteritinib
for Acute Myeloid Leukemia
This phase III trial compares standard chemotherapy to therapy with liposome-encapsulated daunorubicin-cytarabine (CPX-351) and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without FLT3 mutations. Drugs used in chemotherapy, such as daunorubicin, cytarabine, and gemtuzumab ozogamicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. CPX-351 is made up of daunorubicin and cytarabine and is made in a way that makes the drugs stay in the bone marrow longer and could be less likely to cause heart problems than traditional anthracycline drugs, a common class of chemotherapy drug. Some acute myeloid leukemia patients have an abnormality in the structure of a gene called FLT3. Genes are pieces of DNA (molecules that carry instructions for development, functioning, growth and reproduction) inside each cell that tell the cell what to do and when to grow and divide. FLT3 plays an important role in the normal making of blood cells. This gene can have permanent changes that cause it to function abnormally by making cancer cells grow. Gilteritinib may block the abnormal function of the FLT3 gene that makes cancer cells grow. The overall goals of this study are, 1) to compare the effects, good and/or bad, of CPX-351 with daunorubicin and cytarabine on people with newly diagnosed AML to find out which is better, 2) to study the effects, good and/or bad, of adding gilteritinib to AML therapy for patients with high amounts of FLT3/ITD or other FLT3 mutations and 3) to study changes in heart function during and after treatment for AML. Giving CPX-351 and/or gilteritinib with standard chemotherapy may work better in treating patients with acute myeloid leukemia compared to standard chemotherapy alone.
Recruiting2 awards Phase 3
More about Emi H. Caywood
Clinical Trial Related6 years of experience running clinical trials · Led 23 trials as a Principal Investigator · 7 Active Clinical TrialsTreatments Emi H. Caywood has experience with
- Nivolumab
- Cyclophosphamide
- Etoposide
- Dexamethasone
- Methotrexate
- Daunorubicin Hydrochloride
Breakdown of trials Emi H. Caywood has run
Acute Lymphoblastic Leukemia
Acute Leukemia
Burkitt Lymphoma
Acute Myelogenous Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Emi H. Caywood specialize in?
Emi H. Caywood focuses on Acute Lymphoblastic Leukemia and Acute Leukemia. In particular, much of their work with Acute Lymphoblastic Leukemia has involved Stage IV patients, or patients who are BCR-ABL1 fusion positive.
Is Emi H. Caywood currently recruiting for clinical trials?
Yes, Emi H. Caywood is currently recruiting for 7 clinical trials in Wilmington Delaware. If you're interested in participating, you should apply.
Are there any treatments that Emi H. Caywood has studied deeply?
Yes, Emi H. Caywood has studied treatments such as Nivolumab, Cyclophosphamide, Etoposide.
What is the best way to schedule an appointment with Emi H. Caywood?
Apply for one of the trials that Emi H. Caywood is conducting.
What is the office address of Emi H. Caywood?
The office of Emi H. Caywood is located at: Alfred I duPont Hospital for Children, Wilmington, Delaware 19803 United States. This is the address for their practice at the Alfred I duPont Hospital for Children.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.